NICOLAS II期试验:纳武利尤单抗联合同步放化疗治疗IIIA-B期NSCLC的疗效
NICOLAS研究是首个在III期NSCLC中评估纳武利尤单抗联合同步放化疗的单臂II期试验,先前已报告安全性,本文报告疗效。79例患者接受3周期铂类化疗、同步放疗(66 Gy/33次)及纳武利尤单抗(360 mg,每3周),后纳武利尤单抗单药巩固最长1年(480 mg,每4周)。主要终点1年PFS率为53.7%(95%CI 42.0%-64.0%),但分层分析未能拒绝1年PFS率至少45%的原假设(p=0.23)。中位OS为38.8个月(95%CI 26.8-不可估计),2年OS率63.7%(95%CI 51.9%-73.4%)。
要点
- 1年PFS率53.7%,但未达到预设的统计学显著性(p=0.23)。
- 中位OS 38.8个月,2年OS率63.7%。
- IIIA期患者2年OS率81%,显著高于IIIB期的56%(p=0.037)。
核心结论
- 尽管1年PFS率和OS数值上高于历史数据,但正式分层疗效分析未能拒绝1年PFS率至少45%的原假设。
研究设计与样本
- 单臂II期试验,纳入不可切除的IIIA-B期初治NSCLC患者,样本量74例可评估患者提供83%把握度(单侧α=5%)。
主要发现
- 1年PFS率为53.7%(95%CI 42.0%-64.0%),中位PFS为12.7个月(95%CI 10.1-22.8个月)。
- 中位随访32.6个月时,中位OS为38.8个月(95%CI 26.8个月-不可估计),2年OS率为63.7%(95%CI 51.9%-73.4%)。
- IIIA期患者2年OS率为81%,IIIB期患者为56%,差异显著(p=0.037)。
关键数值与推荐
- 主要终点1年PFS率目标从45%提高至60%,但实际1年PFS率为53.7%,未达到统计学显著性(p=0.23)。
临床怎么用
- 该方案在III期NSCLC中显示出数值上较高的PFS和OS,但需进一步随机试验验证。
局限性
- 单臂设计,样本量较小,统计效能有限,未能达到主要终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The NICOLAS study is the first completed single-arm phase II trial in stage III NSCLC evaluating hierarchically first the safety and then the efficacy of adding nivolumab concurrently to standard definitive concurrent chemoradiotherapy. The safety end point was reported earlier; here, we present the efficacy results. METHODS: Stage IIIA-B unresectable treatment-naive patients with NSCLC received three cycles of platinum-based chemotherapy and concurrent radiotherapy (66 Gy, 33 fractions), along with nivolumab (360 mg, 3-weekly). Nivolumab was continued as monotherapy consolidation for a maximum of 1 year (480 mg, 4-weekly). The primary end point was 1-year progression-free survival (PFS), with a target improvement compared with historical data of at least 15%, from 45% to 60%. To test this efficacy hypothesis, a sample size of 74 assessable patients provided a power of 83% with a one-sided alpha of 5%. RESULTS: A total of 79 patients were enrolled with a median follow-up of 21.0 months (interquartile range: 15.8-25.8 mo) for the primary PFS analysis. A total of 35.4% of the patients had stage IIIA, and 63.3% had stage IIIB disease. The 1-year PFS was 53.7% (95% confidence interval [CI]: 42.0%-64.0%) and the median PFS was 12.7 months (95% CI: 10.1-22.8 mo). Because 37 PFS events occurred in the first year posttreatment among the first 74 assessable patients, a 1-year PFS rate of at least 45% could not be rejected (p = 0.23). At an extended follow-up (median 32.6 mo), 37 deaths have been recorded, with a median overall survival (OS) of 38.8 months (95% CI: 26.8 mo-not estimable) and a 2-year OS rate of 63.7% (95% CI: 51.9%-73.4%). The OS of patients with stage IIIA disease was found to be significantly higher than patients with stage IIIB disease, with a 2-year OS of 81% and 56%, respectively (p = 0.037). CONCLUSIONS: PFS and OS are arithmetically higher in studies involving the same population. However, on the basis of the formal hierarchical efficacy analysis, we could not reject that the 1-year PFS rate is at least 45%.
引用
- Peters S, Felip E, Dafni U, et al. Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). J Thorac Oncol. 2020. PMID: 33188912. doi:10.1016/j.jtho.2020.10.129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。